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Ipilimumab is amonoclonal antibody that works as an immunotherapeutic agent through selective targeting of T cells to strengthen
the response to metastatic melanoma. It is well known that this pharmaceutical agent can cause the adverse effect of colitis. We
report a rare presentation of ileocolitis refractory to both glucocorticosteroids and infliximab with a resultant pneumatosis and
perforation requiring subtotal colectomy and end ileostomy.
1. Introduction
The incidence ofmelanomahas been increasing and currently
132,000 melanoma skin cancer cases occur globally each
year [1]. In the United States, it is estimated that 87,110
new cases and 9,730 deaths will result in 2017 alone [2].
Ipilimumab (Yervoy) is an immunotherapeutic agent utilized
for the treatment of metastatic melanoma. Ipilimumab works
as a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
to potentiate the antitumor T-cell response [3]. The most
common immune-mediated adverse event associated with
ipilimumab is enterocolitis [4]. A case report of ipilimumab-
inducing ileocolitis that was refractory to both glucocorticos-
teroid and infliximab therapy has rarely been presented in the
literature.
2. Case Report
A 39-year-old male presented to our institution with a 3-
week history of nausea, vomiting, and diarrhea. Medical
history was notable for occipital melanoma excised in 2011.
Subsequently during a dental procedure in 2016, the patient
was noted to have left sided lymphadenopathy. He underwent
a lymph node biopsy, which was positive for metastatic
melanoma which resulted in a full neck dissection. Two
months thereafter and four weeks prior to his symptom
onset, his primary oncologist started him on ipilimumab.
The patient then presented to the medical intensive care unit
with hypovolemic shock secondary to intractable diarrhea.
In addition to fluid resuscitation, patient was continued on
his prednisone 50mg oral twice daily which had been started
by his oncologist. Patient’s severe diarrhea persisted which
prompted endoscopic examination. Colonoscopy showed
circumferential, diffuse, edematous, erythematous, and fri-
able mucosa with superficial ulcerations along the entire
length of the colon and the terminal ileum (Figures 1(a)
and 1(b)). Pathology from the biopsies obtained during the
colonoscopy was consistent with chronic active ileocolitis
with acute cryptitis, crypt abscess, and granulation tissue
(Figures 2(a) and 2(b)). The steroid regimen was conse-
quently changed to intravenous methylprednisolone 20mg
every 8 hours. The patient also underwent a computed
tomography enterography which demonstrated narrowing of
the distal and terminal ileum as well as a short segment
of narrowing in the mid ileum with fecalization in the
distal ileum (Figure 3). Additionally, pericolonic strand-
ing was noted to be prominent in the descending colon.
Unfortunately, the patient did not respond to intravenous
methylprednisolone over the course of the next 8 days
and a decision was made to initiate infliximab at 5mg/kg.
Despite the start of infliximab, the patient continued to
worsen with diffuse abdominal pain and persistent diarrhea.
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Figure 1: Colonoscopy displaying circumferential, diffuse, edematous, erythematous, and friable mucosa with superficial ulcerations in the
(a) colon and (b) terminal ileum.
(a) (b)
Figure 2: High-power view of chronic active ileocolitis with acute cryptitis, crypt abscess, and granulation tissue in the (a) colon and (b)
terminal ileum.
A repeat computed tomography of the abdomen and pelvis
showed prominent ascending and transverse colitis with
pneumatosis of the distal small bowel, perforated abdominal
viscus withmoderate pneumoperitoneum and pneumomedi-
astinum (Figure 4). The patient underwent a subtotal colec-
tomy with end ileostomy. The patient’s symptoms improved
thereafter and almost a month into the hospital admission,
the patient was discharged on an oral methylprednisolone
taper.
3. Discussion
In a randomized controlled trial, ipilimumab showed sig-
nificant improvement in overall survival of patients with
metastatic melanoma [3]. However, along with the pharma-
cotherapy well-documented immune-related adverse events
have come [4]. In a phase III trial, 60% of patients treated
with ipilimumab experienced immune-related adverse events
[5]. Esophagitis, gastritis, ileitis, and colitis have all been
reported in the literature and given the potential for this
pharmacologic agent to deregulate the immune system,
an adverse reaction can occur in any organ in the body.
With regard to autoimmune colitis, recommendations for
initiation of steroids and infliximab for steroid-refractory
cases have proven to be life-saving [6]. However, when a
case of ileocolitis proves to be refractory to both steroids
and infliximab with a resulting perforation, surgical inter-
vention is ultimately pursued. As immunotherapeutic agents
become commonplace, it is important for gastroenterologists
to remain attentive and keenly observant for complications
with an emphasis placed upon early intervention.
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Figure 3: Coronal view from CT enterography demonstrating
narrowing of the distal and terminal ileum as well as a short
segment of narrowing in the mid ileum (arrow) with fecalization in
the distal ileum.
Figure 4: Axial view from CT abdomen exhibiting prominent
ascending and transverse colitis with pneumatosis (arrow) of the
distal small bowel, perforated abdominal viscus with moderate
pneumoperitoneum and pneumomediastinum.
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